Moderna announced on Wednesday that it will seek urgent permission for the COVID-19 vaccine for children under the age of five. The vaccine is said to be about 44% effective in preventing mild infections in infants up to 2 years old and almost 38% effective in preschoolers.
Dr. Bill Muller, a pediatric infectious disease expert at Northwestern University, is leading a clinical trial of COVID-19 in Moderna. vaccination Children under the age of 12 at Anne & Robert H. Lurie Children’s Hospital in Chicago answered some questions about the news.
Muller is an associate professor of pediatrics at Northwestern University School of Medicine, Fineberg School of Medicine, and a science director of clinical and community trials at the Stanley Manne Children’s Research Institute, which is part of Lurie Children’s.
These efficacy rates appear to be lower than the adult efficacy rates seen with the original adult COVID-19 vaccine. They are?
Muller: The infection-preventing effect may sound modest, but it is actually within the range found in adults with the Omicron variant. I think it’s worth reminding people that the purpose of vaccines is to prevent serious illnesses. We strive to prevent people from getting sick enough to need to be in the hospital or need ICU level care.Prevention of symptomatic diseases is a very high standard to meet and the ability to demonstrate this in these infant It’s an important discovery.
It should be remembered that the benefits of vaccines are likely to exceed those we are studying. In addition to significantly reducing the risk of severe and symptomatic illnesses and moderately reducing the risk of symptomatic illnesses, it may also benefit from reducing the spread of the virus within the community and family. I have. Also, preventing the spread will allow children to stay in school and day care. This means that the parents are scrambling accordingly. Childcare Or the job itself is missing.
How does the antibody response in children compare to adults? And what does that mean for the possibility they need boosters?
Mueller: Regarding the response of children to the vaccine, the antibody response was similar to that seen in adults. This suggests that the response to the vaccine is as good as we have observed in adults. That said, I think most people in this area will eventually expect a third dose in all age groups.
How did the emergence of the Omicron variant affect the results of this Moderna trial under 6 years of age?
Muller: Vaccines that use mRNA sequences that match Omicron are very likely to provide better protection than those used. More trials are needed to investigate this, but two things to keep in mind are that current vaccines are already very good and that omicron-specific vaccines are better than current vaccines for the future. Is also not guaranteed to provide good protection. Subspecies.
How safe is it?
Mueller: One of the things I would like to emphasize when discussing these trials is the excellent safety profile found in vaccines.I think when parents ask themselves if they should get their vaccine Young children, They properly assess their comfort against the risk of infection against the risks that may be associated with the vaccine. These vaccines are extremely safe and have side effects comparable to other pediatric vaccines.but ChildrenInfections are worse than any side effect of the vaccine.
Quote: Prolonged questions about the vaccine efficacy of Moderna in children under 5 years old (March 25, 2022) https: //medicalxpress.com/news/2022-03-lingering-moderna-vaccine-efficacy-kids.html Obtained from March 25, 2022.
This document is subject to copyright. No part may be reproduced without written permission, except for fair transactions for personal investigation or research purposes. Content is provided for informational purposes only.
Prolonged questions about the vaccine efficacy of Moderna in children under 5 years of age
Source link Prolonged questions about the vaccine efficacy of Moderna in children under 5 years of age